Won-Keun Kim1, MD; Corrado Tamburino2, MD, PhD; Helge Möllmann3, MD; Matteo Montorfano4, MD; Julia Ellert-Gregersen5, MD; Tanja K Rudolph6, MD; Nicolas M. Van Mieghem7, MD, PhD; Michael Hilker8, MD; Ignacio J. Amat-Santos9, MD, PhD; Christian Juhl Terkelsen10, MD, DMSc; Anna Sonia Petronio11, MD; Pieter R. Stella12, MD, PhD; Matthias Götberg13, MD, PhD; Andreas Rück14, MD, PhD; A. Markus Kasel15, MD; Ramiro Trillo16, MD; Clare Appleby17, MBChB, PhD; Marco Barbanti2, MD; Philipp Blanke18, MD; Rodrigo Modolo19, MD, PhD; Dominic J. Allocco19, MD; Lars Sondergaard20, MD, DMSc
1. Kerckhoff-Klinik GmbH, Bad Nauheim, Germany; 2. Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico-San Marco, Catania, Italy; 3. St.-Johannes-Hospital Dortmund, Dortmund, Germany; 4. Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy; 5. Department of Cardiology, Odense University Hospital, Odense, Denmark; 6. Heart and Diabetes Center Northrhine-Westphalia, Bad Oeynhausen, Germany; 7. Erasmus Medical Center, Rotterdam, the Netherlands; 8. Universitätsklinik Regensburg, Regensburg, Germany; 9. Hospital Clínico Universitario de Valladolid, Valladolid, Spain; 10. Aarhus University Hospital, Aarhus, Denmark; 11. Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; 12. University Medical Center Utrecht, Utrecht, Netherlands; 13. Department of Cardiology, Skane University Hospital, Lund University, Lund, Sweden; 14. Karolinska University Hospital, Stockholm, Sweden; 15. Universitätsspital Zürich, Zürich, Switzerland; 16. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela. Centro de Investigación Biomedica en Red Enfermedades Cardiovasculares - CIBERCV, Madrid, Spain; 17. Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; 18. Department of Radiology, St Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada; 19. Boston Scientific Corporation, Marlborough, MA, USA; 20. The Heart Center, Rigshospitalet, Copenhagen, Demark
Background: The next-generation ACURATE neo2 transcatheter aortic valve was designed for simplified implantation and to mitigate the risk of paravalvular leak (PVL) compared to the earlier device.
Aims: To collect clinical outcomes and device performance data, including echocardiography and 4-dimensional computed tomography (4D-CT) data, with the ACURATE neo2 transcatheter heart valve in patients with severe aortic stenosis (AS).
Methods: ACURATE neo2 PMCF is a single-arm, multicentre study of patients with severe AS treated in routine clinical practice. The primary safety endpoint was all-cause mortality at 30-days. The primary imaging endpoint was hypo-attenuated leaflet thickening (HALT), measured by core laboratory-adjudicated 4D-CT at 30 days. Secondary endpoints included VARC safety endpoints, procedural success, and evaluation of valve performance via core laboratory-adjudicated echocardiography.
Results: The study enrolled 250 patients at 18 European centres (mean age: 80.8 years; 63.6% female; mean STS score: 2.9±2.0%); 246 (98.4%) were successfully treated with ACURATE neo2. The 30-day rates for mortality and disabling stroke were 0.8% and 0%, respectively. The new permanent pacemaker implantation rate was 6.5%. HALT >50% was present in 9.3% of patients at 30 days. Valve haemodynamics improved from baseline to 30 days (mean aortic valve gradient: from 47.6±14.5 mmHg to 8.6±3.9 mmHg; mean aortic valve area: from 0.7±0.2 cm2 to 1.6±0.4 cm2). At 30 days, PVL was evaluated as none/trace in 79.2% of patients, mild in 18.9%, moderate in 1.9%, and severe in 0%.
Conclusions: The study results support the safety and efficacy of TAVI with ACURATE neo2 in patients in routine clinical practice.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
aortic stenosisfemoraltavimscttransesophageal echocardiogram
Interventions for valvular diseaseTAVI
Read next article
Transcatheter aortic valve implantation of a novel system for severe pure native aortic regurgitation in a patient with ascending aorta aneurysm